Department of Public Health and Sport Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.
Eur J Nutr. 2024 Apr;63(3):869-879. doi: 10.1007/s00394-023-03310-w. Epub 2024 Jan 12.
Shatavari is an understudied, widely available herbal supplement. It contains steroidal saponins and phytoestrogens. We previously showed that six weeks of shatavari supplementation improved handgrip strength and increased markers of myosin contractile function. Mechanistic insights into shatavari's actions are limited. Therefore, we performed proteomics on vastus lateralis (VL) samples that remained from our original study.
In a randomised double-blind trial, women (68.5 ± 6 years) ingested either placebo or shatavari (equivalent to 26,500 mg/d fresh weight) for six weeks. Tandem mass tag global proteomic analysis of VL samples was conducted (N = 7 shatavari, N = 5 placebo). Data were normalized to total peptides and scaled using a reference sample. Data were filtered using a 5% FDR. For each protein, the pre to post supplementation difference was expressed as log2 fold change. Welch's t tests with Benjamini-Hochberg corrections were performed for each protein. Pathway enrichment (PADOG, CAMERA) was interrogated in Reactome (v85).
No individual protein was significantly different between supplementation conditions. Both PADOG and CAMERA indicated that pathways related to (1) Integrin/MAPK signalling, (2) metabolism/insulin secretion; (3) cell proliferation/senescence/DNA repair/cell death; (4) haemostasis/platelets/fibrin; (5) signal transduction; (6) neutrophil degranulation and (7) chemical synapse function were significantly upregulated. CAMERA indicated pathways related to translation/amino acid metabolism, viral infection, and muscle contraction were downregulated.
Our analyses indicate that shatavari may support muscle adaptation responses to exercise. These data provide useful signposts for future investigation of shatavari's utility in conserving and enhancing musculoskeletal function in older age.
NCT05025917 30/08/21, retrospectively registered.
夏塔瓦里是一种研究不足但广泛可用的草药补充剂。它含有甾体皂甙和植物雌激素。我们之前的研究表明,六周的夏塔瓦里补充剂可以提高握力,增加肌球蛋白收缩功能的标志物。对夏塔瓦里作用的机制了解有限。因此,我们对来自原始研究的股外侧肌 (VL) 样本进行了蛋白质组学分析。
在一项随机双盲试验中,女性(68.5±6 岁)服用安慰剂或夏塔瓦里(相当于 26500mg/d 新鲜重量)六周。对 VL 样本进行串联质量标签全蛋白质组分析(夏塔瓦里组 N=7,安慰剂组 N=5)。数据按总肽归一化,并使用参考样本进行缩放。使用 5% FDR 过滤数据。对于每种蛋白质,用对数 2 倍变化表示补充前后的差异。对每个蛋白质进行 Welch 检验和 Benjamini-Hochberg 校正。在 Reactome(v85)中使用 PADOG 和 CAMERA 进行途径富集分析。
没有一种蛋白质在补充条件之间有显著差异。PADOG 和 CAMERA 都表明,与(1)整合素/MAPK 信号转导、(2)代谢/胰岛素分泌、(3)细胞增殖/衰老/DNA 修复/细胞死亡、(4)止血/血小板/纤维蛋白、(5)信号转导、(6)嗜中性粒细胞脱粒和(7)化学突触功能相关的途径显著上调。CAMERA 表明与翻译/氨基酸代谢、病毒感染和肌肉收缩相关的途径下调。
我们的分析表明,夏塔瓦里可能支持运动对肌肉适应的反应。这些数据为未来研究夏塔瓦里在老年时维持和增强肌肉骨骼功能的效用提供了有用的线索。
NCT05025917,于 2021 年 8 月 30 日进行了回顾性注册。